Smith, Moore & Co’s Elevance Health ELV Stock Holding History

Smith, Moore & Co’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.14M	Hold	3,896	–	–	0.08%	191
2025 Q4	$1.37M	Sell	3,896 -6	-0.2%	-$2.03K	0.1%	163
2025 Q3	$1.26M	Sell	3,902 -22	-0.6%	-$6.84K	0.1%	175
2025 Q2	$1.53M	Hold	3,924	–	–	0.13%	151
2025 Q1	$1.71M	Buy	3,924 +22	+0.6%	+$8.83K	0.16%	130
2024 Q4	$1.44M	Sell	3,902 -31	-0.8%	-$13K	0.13%	143
2024 Q3	$2.05M	Hold	3,933	–	–	0.2%	103
2024 Q2	$2.13M	Hold	3,933	–	–	0.22%	94
2024 Q1	$2.04M	Buy	3,933 +75	+2%	+$37.3K	0.22%	91
2023 Q4	$1.82M	Sell	3,858 -44	-1%	-$20.3K	0.21%	93
2023 Q3	$1.7M	Sell	3,902 -8	-0.2%	-$3.63K	0.22%	91
2023 Q2	$1.74M	Sell	3,910 -2	-0.1%	-$923	0.22%	92
2023 Q1	$1.8M	Hold	3,912	–	–	0.24%	84
2022 Q4	$2.01M	Buy	3,912 +2	+0.1%	+$1.01K	0.28%	75
2022 Q3	$1.78M	Hold	3,910	–	–	0.27%	77
2022 Q2	$1.89M	Hold	3,910	–	–	0.29%	77
2022 Q1	$1.92M	Sell	3,910 -15	-0.4%	-$6.86K	0.26%	77
2021 Q4	$1.82M	Hold	3,925	–	–	0.25%	74
2021 Q3	$1.46M	Hold	3,925	–	–	0.22%	86
2021 Q2	$1.5M	Hold	3,925	–	–	0.23%	82
2021 Q1	$1.41M	Hold	3,925	–	–	0.23%	89
2020 Q4	$1.26M	Hold	3,925	–	–	0.24%	79
2020 Q3	$1.05M	Sell	3,925 -81	-2%	-$21.8K	0.22%	90
2020 Q2	$1.05M	Hold	4,006	–	–	0.23%	80
2020 Q1	$910K	Hold	4,006	–	–	0.24%	81
2019 Q4	$1.21M	Sell	4,006 -70	-2%	-$19.3K	0.25%	75
2019 Q3	$979K	Sell	4,076 -20	-0.5%	-$5.48K	0.22%	88
2019 Q2	$1.16M	Hold	4,096	–	–	0.26%	73
2019 Q1	$1.18M	Sell	4,096 -59	-1%	-$17.1K	0.28%	69
2018 Q4	$1.09M	Hold	4,155	–	–	0.3%	65
2018 Q3	$1.14M	Hold	4,155	–	–	0.26%	75
2018 Q2	$989K	Hold	4,155	–	–	0.25%	77
2018 Q1	$913K	Hold	4,155	–	–	0.24%	79
2017 Q4	$935K	Buy	4,155 +145	+4%	+$30.9K	0.25%	78
2017 Q3	$761K	Sell	4,010 -250	-6%	-$47.6K	0.22%	90
2017 Q2	$801K	Hold	4,260	–	–	0.27%	71
2017 Q1	$705K	Hold	4,260	–	–	0.25%	75
2016 Q4	$612K	Hold	4,260	–	–	0.23%	81
2016 Q3	$534K	Hold	4,260	–	–	0.21%	92
2016 Q2	$560K	Hold	4,260	–	–	0.23%	88
2016 Q1	$592K	Buy	4,260 +50	+1%	+$6.68K	0.26%	82
2015 Q4	$587K	Buy	4,210 +500	+13%	+$68.9K	0.29%	71
2015 Q3	$519K	Buy	3,710 +250	+7%	+$37.6K	0.29%	61
2015 Q2	$568K	Buy	3,460 +59	+2%	+$9.43K	0.29%	59
2015 Q1	$525K	Hold	3,401	–	–	0.28%	69
2014 Q4	$427K	Sell	3,401 -100	-3%	-$12.4K	0.23%	87
2014 Q3	$419K	Buy	+3,501	New	+$402K	0.23%	88
2014 Q2	–	Sell	-3,320	Closed	-$331K	–	150
2014 Q1	$331K	Hold	3,320	–	–	0.2%	102
2013 Q4	$307K	Buy	+3,320	New	+$295K	0.19%	106

Other funds holding ELV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Smith, Moore & Co's ELV Position: Q1 2026 in Review

Smith, Moore & Co held its Elevance Health (ELV) position steady in Q1 2026 at 3,896 shares worth $1.14M. The position accounts for 0.08% of the portfolio, ranked #191.

Smith, Moore & Co first reported a position in ELV in Q4 2013 and has held it in 49 quarters since. The position peaked at $2.13M in Q2 2024. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.

Smith, Moore & Co held 3,896 shares of Elevance Health worth $1.14M as of Q1 2026.
Smith, Moore & Co left its Elevance Health share count unchanged in Q1 2026.
Elevance Health made up 0.08% of Smith, Moore & Co's portfolio in Q1 2026, its #191 holding.
Smith, Moore & Co first reported a position in Elevance Health in Q4 2013 and has held it in 49 quarters since.
Smith, Moore & Co's Elevance Health position peaked at $2.13M in Q2 2024.
1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.

Based on Smith, Moore & Co's 13F filing for Q1 2026, filed 5 May 2026.